Medical device maker Thermo Fisher Scientific Inc said on Friday it has completed acquisition of Henogen SA, a Belgium-based viral vector manufacturing business, for about 725 million euros ($879.72 million) in cash.
The acquisition will help expand Thermo Fisher's capabilities for cell and gene vaccines and therapies, the company said.
Thermo Fisher bought Henogen from contract manufacturing services provider Novasep.
Comments
Comments are closed for this article.